{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:50:23Z","timestamp":1791111023331,"version":"4.1.0"},"reference-count":37,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objective of the investigation was to study the efficacy and safety of daily oral alendronate (ALN) in children with OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design and Participants:<\/jats:title>\n                  <jats:p>We conducted a multicenter, double-blind, randomized, placebo-controlled study. One hundred thirty-nine children (aged 4\u201319 yr) with type I, III, or IV OI were randomized to either placebo (n = 30) or ALN (n = 109) for 2 yr. ALN doses were 5 mg\/d in children less than 40 kg and 10 mg\/d for those 40 kg and greater.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>Spine areal bone mineral density (BMD) z-score, urinary N-telopeptide of collagen type I, extremity fracture incidence, vertebral area, iliac cortical width, bone pain, physical activity, and safety parameters were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>ALN increased spine areal BMD by 51% vs. a 12% increase with placebo (P &amp;lt; 0.001); the mean spine areal BMD z-score increased significantly from \u22124.6 to \u22123.3 (P &amp;lt; 0.001) with ALN, whereas the change in the placebo group (from \u22124.6 to \u22124.5) was insignificant. Urinary N-telopeptide of collagen type I decreased by 62% in the ALN-treated group, compared with 32% with placebo (P &amp;lt; 0.001). Long-bone fracture incidence, average midline vertebral height, iliac cortical width, bone pain, and physical activity were similar between groups. The incidences of clinical and laboratory adverse experiences were also similar between the treatment and placebo groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2010-0636","type":"journal-article","created":{"date-parts":[[2010,11,25]],"date-time":"2010-11-25T03:32:15Z","timestamp":1290655935000},"page":"355-364","source":"Crossref","is-referenced-by-count":191,"title":["Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study"],"prefix":"10.1210","volume":"96","author":[{"given":"L. M.","family":"Ward","sequence":"first","affiliation":[{"name":"Genetics Unit (L.M.W., F.R., F.H.G.), Shriners Hospital for Children, Montr\u00e9al, Qu\u00e9bec, Canada H3G 1A6;"},{"name":"Children's Hospital of Eastern Ontario (L.M.W.), University of Ottawa, Ottawa, Ontario, Canada K1H 8L1;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rauch","sequence":"additional","affiliation":[{"name":"Genetics Unit (L.M.W., F.R., F.H.G.), Shriners Hospital for Children, Montr\u00e9al, Qu\u00e9bec, Canada H3G 1A6;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Whyte","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (M.P.W.), St. Louis, MO 63131;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"D'Astous","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (J.D.), Salt Lake City, Utah 84103;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. E.","family":"Gates","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (P.E.G., R.E.M., T.A.P.), Shreveport, Louisiana 71103;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Grogan","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (D.G.), Tampa, Florida 33612;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"Lester","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (E.L.L.), Spokane, Washington 99204;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"McCall","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (P.E.G., R.E.M., T.A.P.), Shreveport, Louisiana 71103;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A.","family":"Pressly","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (P.E.G., R.E.M., T.A.P.), Shreveport, Louisiana 71103;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. O.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (J.O.S.), Erie, Pennsylvania 16505;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (P.A.S.), Chicago, Illinois 60707;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. D.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (R.D.S.), Portland, Oregon 97239;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (E.S.), Houston, Texas 77030;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tyerman","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (G.T.), Los Angeles, California 90020;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Smith-Wright","sequence":"additional","affiliation":[{"name":"Shriners Hospital for Children (D.L.S.-W.), Twin Cities, Minneapolis, Minnesota 55414;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Verbruggen","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc. (N.V., N.H., A.L.), Whitehouse Station, New Jersey 08889"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Heyden","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc. (N.V., N.H., A.L.), Whitehouse Station, New Jersey 08889"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lombardi","sequence":"additional","affiliation":[{"name":"Merck & Co. Inc. (N.V., N.H., A.L.), Whitehouse Station, New Jersey 08889"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. H.","family":"Glorieux","sequence":"additional","affiliation":[{"name":"Genetics Unit (L.M.W., F.R., F.H.G.), Shriners Hospital for Children, Montr\u00e9al, Qu\u00e9bec, Canada H3G 1A6;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614133731500_B1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","article-title":"Osteogenesis imperfecta.","volume":"363","author":"Rauch","year":"2004","journal-title":"Lancet"},{"key":"2020071614133731500_B2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta.","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"2020071614133731500_B3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1968","article-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta.","volume":"39","author":"Cabral","year":"2007","journal-title":"Nat Genet"},{"key":"2020071614133731500_B4","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ajhg.2010.02.022","article-title":"Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta.","volume":"86","author":"Alanay","year":"2010","journal-title":"Am J Hum Genet"},{"key":"2020071614133731500_B5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ajhg.2010.01.034","article-title":"Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta.","volume":"86","author":"Christiansen","year":"2010","journal-title":"Am J Hum Genet"},{"key":"2020071614133731500_B6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMoa0907705","article-title":"Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding.","volume":"362","author":"Barnes","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071614133731500_B7","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis.","volume":"367","author":"Sambrook","year":"2006","journal-title":"Lancet"},{"key":"2020071614133731500_B8","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study.","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"2020071614133731500_B9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1651-2227.2003.tb00577.x","article-title":"Treatment of children with osteogenesis imperfecta in Estonia.","volume":"92","author":"Maasalu","year":"2003","journal-title":"Acta Paediatr"},{"key":"2020071614133731500_B10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ajcn\/32.3.607","article-title":"Physical growth: National Center for Health Statistics percentiles.","volume":"32","author":"Hamill","year":"1979","journal-title":"Am J Clin Nutr"},{"key":"2020071614133731500_B12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071614133731500_B13","article-title":"Radiographic atlas of skeletal development of the hand and wrist","author":"Greulich","year":"1959","edition":"2nd ed"},{"key":"2020071614133731500_B14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1210\/jcem-70-5-1330","article-title":"Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters.","volume":"70","author":"Glastre","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614133731500_B15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1148\/radiology.179.3.2027984","article-title":"Bone mass in healthy children: measurement with quantitative DXA.","volume":"179","author":"Southard","year":"1991","journal-title":"Radiology"},{"key":"2020071614133731500_B16","article-title":"Pediatric Evaluation of Disability Inventory (PEDI): development, standardization and administrative manual","author":"Haley","year":"1992"},{"key":"2020071614133731500_B17","first-page":"E680","article-title":"Influence of serum Ca concentration on circulating molecular forms of PTH in three species.","volume":"251","author":"D'Amour","year":"1986","journal-title":"Am J Physiol"},{"key":"2020071614133731500_B18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S8756-3282(99)00257-4","article-title":"Normative data for iliac bone histomorphometry in growing children.","volume":"26","author":"Glorieux","year":"2000","journal-title":"Bone"},{"key":"2020071614133731500_B19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee.","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B20","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men.","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2020071614133731500_B21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/8756-3282(94)90888-5","article-title":"Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides.","volume":"15","author":"Bollen","year":"1994","journal-title":"Bone"},{"key":"2020071614133731500_B22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071614133731500_B23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis.","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071614133731500_B25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/JPEM.2010.23.1-2.73","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta.","volume":"23","author":"Salehpour","year":"2010","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071614133731500_B26","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","article-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.","volume":"25","author":"Bishop","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","article-title":"Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614133731500_B29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","article-title":"Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.","volume":"18","author":"Rauch","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"key":"2020071614133731500_B31","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.","volume":"20","author":"Munns","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B33","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614133731500_B34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.","volume":"86","author":"Astr\u00f6m","year":"2002","journal-title":"Arch Dis Child"},{"key":"2020071614133731500_B35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/JPEM.2002.15.2.163","article-title":"Pamidronate treatment of osteogenesis imperfecta\u2014lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.","volume":"15","author":"Zacharin","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2020071614133731500_B36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1359\/jbmr.081225","article-title":"Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.","volume":"24","author":"Cheung","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071614133731500_B37","first-page":"711","article-title":"Nitrogen-containing bisphosphonate mechanism of action.","volume":"4","author":"Reszka","year":"2004","journal-title":"Mini Rev Med Chem"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/2\/355\/9067967\/jcem0355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/2\/355\/9067967\/jcem0355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:41:42Z","timestamp":1594950102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/2\/355\/2709498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2010-0636","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,1]]}}}